1-3 of 3
Makiko Ban-Hoefen, MD
Close
Sort by
Journal Articles

The JAK Inhibitor Ruxolitinib Elicits Hematologic and Symptomatic Improvement In Patients With Chuvash Polycythemia

Makiko Ban-Hoefen, MD, Elizabeth K. Engle, PhD, Eric M. Knoche, MD, Charu Kaiwar, Karyn Gordon, Deborah M. Moore, Stephen T. Oh, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4051.
https://doi.org/10.1182/blood.V122.21.4051.4051
Published: 2013
Journal Articles

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Makiko Ban-Hoefen, MD, Ann Vanderplas, MS, Jennifer L. Kelly, PhD, MPH, Allison Crosby-Thompson, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Joyce Niland, PhD, Ann LaCasce, MD, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2012) 120 (21): 2669.
https://doi.org/10.1182/blood.V120.21.2669.2669
Published: 2012
Journal Articles

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Makiko Ban-Hoefen, MD, Jonathan W. Friedberg, MD, Jennifer L. Kelly, PhD, MPH, Steven H. Bernstein, MD, Jane L. Liesveld, MD, Faith Young, MD, Richard I Fisher, MD, Louis Constine, MD, Michael Becker, MD, Gordon L. Phillips, II, MD
Journal: Blood
Blood (2010) 116 (21): 2393.
https://doi.org/10.1182/blood.V116.21.2393.2393
Published: 2010